Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFANILAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFANILAMIDE.
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE vs SULFANILAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateSulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
Terminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."